Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radioc
The aim of this study is to evaluate modulation of anti-tumor T cell responses in cancer patients treated by concomitant radiochemotherapy (i-RTCT)
| Condition(s) | Lung Cancer, Head and Neck Cancer |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The aim of this study is to evaluate modulation of anti-tumor T cell responses in cancer patients treated by concomitant radiochemotherapy (i-RTCT) |
| Who can participate | Inclusion Criteria: * Histologically confirmed NSCLC (Non Small Cell Lung Cancer) or SCLC (small cell lung cancer) OR histologically confirmed Head and neck cancer * Patient candidate to a first-line concomitant radiochemotherapy * Written informed consent Exclusion Criteria: * Sequential radiochemotherapy, exclusive radiotherapy, or stereotactic radiotherapy * History of adjuvant radiochemotherapy for cancer treatment * Patients under immunotherapy, chemotherapy or other immunosuppressive drugs (prednisone or prednisolone ≤ 10 mg/day is allowed) * HIV, hepatitis C or B virus * Patients with any medical or psychiatric condition or disease, * Patients under guardianship, curatorship or under the protection of justice. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Centre Hospitalier Universitaire de Besancon |
| Locations | Besançon, France; Dijon, France; Montbéliard, France; Reims, France |
| Start date | 2017-05-29 |
| NCT ID | NCT03117946 |
| Official listing | https://clinicaltrials.gov/study/NCT03117946 |